Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Abstrato

Targeted Therapies for Soft Tissue Sarcoma: New Horizons in Treatment

Rhys Moorish*

Soft tissue sarcoma (STS) encompasses a diverse group of rare and challenging malignancies originating from soft tissues. Historically, treatment options have been limited to surgery, radiation, and chemotherapy, often yielding suboptimal outcomes. However, the emergence of targeted therapies has revolutionized the landscape of STS treatment, offering new horizons and renewed hope for patients and clinicians alike. Targeted therapies represent a class of treatments designed to selectively target specific molecular abnormalities or pathways essential for tumor growth and survival. By honing in on these unique molecular targets, targeted therapies aim to achieve higher efficacy with reduced systemic toxicity compared to conventional chemotherapy.